CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Belumosudil (KD025)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02841995
NCT02841995Phase 2Completed
CompareCT.gov

A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

Kadmon, a Sanofi Company·interventional·Posted Jul 22, 2016·Updated Jun 28, 2023

In Brief

A Phase 2 clinical trial evaluating Belumosudil (KD025) for Graft vs Host Disease. Completed, enrolled 54 participants across 7 sites.

Detailed Summary

This study was been conducted to evaluate the safety, tolerability, and activity of belumosudil (formerly known as KD025) in adult participants with chronic graft versus host disease (cGVHD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft vs Host Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 22, 2016
Enrollment StartSep 15, 2016
Primary CompletionMay 12, 2022
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 9.9 years ago

Interventions

Belumosudil (KD025)drug

Pharmaceutical form: Capsules or Tablets Route of administration: Oral